Development of a Communication Tool between Patients and Physicians for Recognizing COPD Exacerbations in Japan

References

• Global strategy for prevention, diagnosis and management of COPD 2021 report – Global initiative for chronic obstructive lung disease [Internet]. [cited 2021 Aug 5]. Available from: https://goldcopd.org/
   Google Scholar
• The JRS Guideline for the Management of Chronic Obstructive Pulmonary Disease 2022 – Japanese Respiratory Society, The Committee for the Sixth Edition of the COPD Guidelines of The Japanese Respiratory Society [Internet]. [cited 2022 Aug 18]. Available from: https://www.jrs.or.jp/publication/jrs_guidelines/20220512084311.html
   Google Scholar
• Calverley PM, Tetzlaff K, Dusser D, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis. 2017;12:3391–3405. doi: 10.2147/copd.s145814.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M, Metzdorf N, et al. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi: 10.2147/COPD.S139470.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–338. doi: 10.1164/rccm.200712-1869OC.
   PubMed Web of Science ®Google Scholar
• Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131(3):696–704. doi: 10.1378/chest.06-1610.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Mullerova H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi: 10.1164/rccm.201710-2029OC.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi: 10.1164/rccm.201711-2239OC.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi: 10.1056/NEJMoa0909883.
   PubMed Web of Science ®Google Scholar
• Linnell J, Hurst JR. COPD exacerbations: a patient and physician’s perspective. Adv Ther. 2020;37(1):10–16. doi: 10.1007/s12325-019-01138-7.
   PubMed Web of Science ®Google Scholar
• Betsuyaku T, Kato M, Fujimoto K, et al. A randomized trial of symptom-based management in Japanese patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2409–2423. doi: 10.2147/COPD.S152723.
   PubMed Web of Science ®Google Scholar
• Ishii T, Nishimura M, Akimoto A, et al. Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. Int J Chron Obstruct Pulmon Dis. 2018;13:3459–3471. doi: 10.2147/COPD.S165187.
   PubMed Web of Science ®Google Scholar
• Korpershoek Y, Vervoort S, Nijssen L, et al. Factors influencing exacerbation-related self-management in patients with COPD: a qualitative study. Int J Chron Obstruct Pulmon Dis. 2016;11:2977–2990. doi: 10.2147/copd.s116196.
   PubMed Web of Science ®Google Scholar
• Mackay AJ, Donaldson GC, Patel AR, et al. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185(11):1218–1224. doi: 10.1164/rccm.201110-1843OC.
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi: 10.1183/09031936.00102509.
   PubMed Web of Science ®Google Scholar
• Jones PW, Chen WH, Wilcox TK, et al. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011;139(6):1388–1394. doi: 10.1378/chest.10-1240.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13(8):965–975. doi: 10.1111/j.1524-4733.2010.00772.x.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care M ed. 2011;183(3):323–329. doi: 10.1164/rccm.201005-0762OC.
   PubMed Web of Science ®Google Scholar
• Jones P, Wang C, Chen P, et al. The development of a COPD exacerbation recognition tool (CERT) to help patients recognize when to seek medical advice. Int J Chron Obstruct Pulmon Dis. 2022;17:213–222. doi: 10.2147/COPD.S337644.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Hara J, Kobayashi T, et al. The prevalence and clinical features of asthma-COPD overlap (ACO) definitively diagnosed according to the Japanese Respiratory Society Guidelines for the Management of ACO 2018. J Med Invest. 2019;66(1.2):157–164. doi: 10.2152/jmi.66.157.
   PubMed Web of Science ®Google Scholar
• Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest. 2011;140(3):626–633. doi: 10.1378/chest.10-2948.
   PubMed Web of Science ®Google Scholar
• Onishi K, Yoshimoto D, Hagan GW, et al. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis. 2014;9:563–568. doi: 10.2147/COPD.S59962.
   PubMed Web of Science ®Google Scholar
• Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54–57. doi: 10.1183/09059180.00001309.
   PubMedGoogle Scholar
• Tamaki K, Sakihara E, Miyata H, et al. Utility of self-administered questionnaires for identifying individuals at risk of COPD in Japan: the OCEAN (Okinawa COPD casE finding AssessmeNt) study. Int J Chron Obstruct Pulmon Dis. 2021;16:1771–1782. doi: 10.2147/COPD.S302259.
   PubMed Web of Science ®Google Scholar
• Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156–1165. doi: 10.1183/09031936.00038814.
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Platt RW, Ernst P, et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177(4):396–401. doi: 10.1164/rccm.200708-1290OC.
   PubMed Web of Science ®Google Scholar
• Lenferink A, Brusse-Keizer M, van der Valk PD, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;8(8):Cd011682. doi: 10.1002/14651858.CD011682.pub2.
   PubMed Web of Science ®Google Scholar